NMC
FLNA

Nine Masts Capital’s Filana Therapeutics FLNA Stock Holding History

Nine Masts Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.8K Buy
+27,107
New +$55.8K 0.01% 150

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Nine Masts Capital's FLNA Position: Q1 2026 in Review

Nine Masts Capital opened a new position in Filana Therapeutics (FLNA) in Q1 2026: 27,107 shares worth $45.8K. The stake represents 0.01% of the portfolio and ranks #150 among its holdings.

101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Nine Masts Capital held 27,107 shares of Filana Therapeutics worth $45.8K as of Q1 2026.
  • Filana Therapeutics was a new Nine Masts Capital position in Q1 2026.
  • Filana Therapeutics made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #150 holding.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.